Table 1 The demographics of patients in study separated by GRs and PRs

From: Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers

 

GRs n = 190

PRs n = 177

 

Age at randomisation (years)

 Median

68

66

 

 <59

19% (37)

29% (51)

p = 0.003 (Fisher-exact)

 60–69

39% (75)

34% (61)

 

 70–79

29% (56)

24% (42)

 

 ≥80

11% (21)

12% (22)

 

 Unknown

1% (1)

1% (1)

 

Tumour size (cm)

 Median

2

2.1

 

 ≤2

55% (104)

46% (81)

 

 >2 & ≤5

43% (82)

51% (91)

 

 >5

2% (3)

1% (2)

 

 Unknown

1% (1)

1% (2)

 

Tumour grade

 G1

8% (16)

7% (12)

 

 G2

61% (115)

45% (79)

p = 0.002 (Fisher-exact)

 G3

24% (45)

41% (72)

p = 0.001 (Fisher-exact)

 Unknown

7% (14)

8% (14)

 

Nodal status

 0

59% (113)

56% (100)

 

 1–3

28% (53)

31% (55)

 

 ≥3

12% (23)

12%(12%)

 

Chemotherapy

 Yes

29% (43)

42% (75)

p = 0.0001 (Fisher-exact)

 Unknown

2% (3)

1% (2)

 

Vascular invasion

 No

61% (115)

58% (103)

 

 Yes

35% (67)

34% (60)

 

 Unknown

4% (8)

8% (14)

 

Histological type

 IDC

83% (157)

88% (155)

 

 ILC

13% (25)

10% (17)

 

 Other

2% (4)

2% (4)

 

 Unknown

2% (4)

1% (1)

 

Ki67 % Baseline

 Median

26% (range 10% to 73%)

29% (range 10% to 97%)

 

Ki67 % 2wk

 Median

2% (range 0% to 11%)

24% (range 6% to 95%)

p = 1.16 × 10−60 (Mann–Whitney)

Ki67 % Change

 Median

−91% (range −80 to −100%)

−14% (range 48% to 184%)

p = 1.42 × 10−61 (Mann–Whitney)

  1. Significant differences (p < 0.05) between Grs and PRs determined by two-sided Fisher’s exact test for categories and by two-sided Mann–Whitney test for continuous variables (Ki67).
Back to article page